Loading the company…
Loading the company…
㈜한국씨앤비
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Incheon, founded in 2021. Industry: Cosmetics (K-Beauty). Revenue for 2025 was ₩30.4bn. It has 67 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2022-09-07 · latest registration 2023-07-24 · newest first
본 발명은 병풀을 3 단계 발효과정을 통해 면역활성물질의 함량이 증가된 병풀 발효 추출물을 제조하는 방법 및 이를 포함하는 화장료 조성물에 관한 것이다. 본 발명에 따라 3 단계 발효과정을 통해 수득한 병풀 발효 추출물은 면역활성물질인 마데카소사이드, 아시아티코사이드, 마데카식산 및 아시아틱산의 함량이 유기용매 추출한 경우에 비해 크게 증가하여, 3 단계 발효과정을 통한 병풀 발효 추출물을 포함하는 화장료 조성물은 피부면역 뿐만 아니라 생체면역 증강 효과가 있어 유용하다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 10.9 | 30.4 |
| Cost of sales | 9.1 | 24.1 |
| Gross profit (loss) | 1.8 | 6.3 |
| Selling, general and administrative expenses | 1.0 | 1.3 |
| Operating income (loss) | 0.8 | 5.0 |
| Non-operating income | 0.0 | 0.1 |
| Other gains | 0.0 | 0.0 |
| Finance income | 0.0 | 0.0 |
| Other | — | 0.0 |
| Non-operating expenses | 0.4 | 0.3 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.4 | 0.3 |
| Profit (loss) before tax | 0.4 | 4.7 |
| Income tax expense | 0.0 | 0.4 |
| Net income (loss) | 0.4 | 4.4 |
Revenue ₩30.4bn, up 177.9% YoY.
Operating margin 16.4% (prior 7.4%).
Net income ₩4.4bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06